Abstracts tagged "SLE"

Abstract Number: 1581 • 2013 ACR/ARHP Annual Meeting
Lipid Lowering Medication Use Is Associated With Reduced Muscle Strength In Systemic Lupus Erythematosus
James S. Andrews¹ and Patricia P. Katz², ¹Rheumatology, University of California San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: Premature atherosclerotic coronary artery disease is a major source of morbidity for women with systemic lupus erythematosus (SLE). Lipid lowering medications (LLM) are among…
Abstract Number: 604 • 2013 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Is Not Associated With Reduced Cardiovascular Or Lupus Damage Accumulation In a Cross-Sectional Lupus Cohort Study
Maureen A. McMahon¹, Maria Dall'era², Eliza Chakravarty³, Joseph E. Craft⁴, Gary S. Gilkeson⁵, Kenneth C. Kalunian⁶, R. John Looney⁷, Gerald McGwin Jr.⁸ and Meggan Mackay⁹, ¹Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Yale University School of Medicine, Internal Medicine, Section of Rheumatology, New Haven, CT, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶UCSD School of Medicine, La Jolla, CA, ⁷Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁸Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁹Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Mycophenolate mofetil (MMF) is frequently used for the treatment of lupus. The immune-modulating effects of MMF extend beyond effects on lymphocyte proliferation, and include…
Abstract Number: 34 • 2013 ACR/ARHP Annual Meeting
Dichotomous Responses Of Human Systemic Lupus Erythematosus B Cell Subsets To B Cell Receptor Stimulation
Franziska Matzkies¹, Anthony DeFranco², Andrew J. Gross³, Maria Dall'era⁴ and Michelle Hermiston⁵, ¹Medicine- Rheumatology, University of California, San Francisco, San Francisco, CA, ²Microbiology & Immunology, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵Pediatrics, Hematology/Oncology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Autoantibody production is a hallmark of Systemic Lupus Erythematosus (SLE), supporting a central role for B cells in disease pathogenesis. Prior studies have demonstrated…
Abstract Number: 2722 • 2013 ACR/ARHP Annual Meeting
In Vivo Administration Of MiR-146a Protects C57BL/6 Mice From Pristane-Induced Pulmonary Hemorrhage Via Suppressing Type I Interferon Response
Dong Liang¹, Shiyu Zhou², Zheng Liu³, Zhengyuan Shan¹, Philip Brohawn³, Yihong Yao³, John B. Harley^4,5 and Nan Shen^1,2,6, ¹Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁴Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁶Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: miR-146a as an endogenous regulator plays a critical role in resolving acute inflammation. The risk-associated genetic variant in miR-146a promoter was linked to reduced…
Abstract Number: 1636 • 2013 ACR/ARHP Annual Meeting
Pro-Inflammatory HDL and Subclinical Atherosclerosis Are Associated With Altered Expression Of Epigenetic and Oxidative Stress-Related Gene Transcripts In SLE
Brian Skaggs¹, Bevra H. Hahn², Jennifer M. Grossman³, Elaine Lourenco¹, Isao Matsuura⁴, Lori Sahakian⁵ and Maureen A. McMahon⁶, ¹Medicine/Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Division of Rheumatology, Department of Medicine,, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁶Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Premature atherosclerosis is widely recognized as a significant co-morbid condition of systemic lupus erythematosus (SLE), but exact mechanisms are unknown. Although traditional cardiovascular risk…
Abstract Number: 1061 • 2013 ACR/ARHP Annual Meeting
Clinical Phenotypes and Disease Burden Of Discoid Lupus Erythematosus In a Sample Of Systemic Lupus Erythematosus Patients In The Southeastern United States
Leslie Anne Cassidy¹, Gaobin Bao², Charmayne M. Dunlop-Thomas³, S. Sam Lim⁴ and Cristina Drenkard^5,6, ¹Department of Medicine, Division of Rheumatology, Emory University, Atlanta, GA, ²Medicine, Emory University, Atlanta, GA, ³Medicine Rheumatology, Emory University, Atlanta, GA, ⁴Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ⁵Department of Medicine, Emory University, Atlanta, GA, ⁶Epidemiology, Emory Rollins School of Public Health, Atlanta, GA
Background/Purpose: The rash of discoid lupus erythematosus (DLE) has been reported in 10-25% of patients with systemic lupus erythematosus (SLE). Prior reports suggest that DLE…
Abstract Number: 605 • 2013 ACR/ARHP Annual Meeting
Childhood Lupus Nephritis: Long Term Outcome Of 91biopsy Proven Cases From India
Puja Srivastava¹, Bonnie Abujam², Ramnath Misra¹, Able Lawrence¹, Vikas Agarwal¹ and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Childhood SLE has a higher prevalence of lupus nephritis (LN) as well as proliferative LN than adults. There is ethnic variation in response to…
Abstract Number: 2724 • 2013 ACR/ARHP Annual Meeting
cAMP Responsive Element Modulator (CREM)α Governs CD8 Expression and Contributes to the Generation of CD3⁺CD4^–CD8^– T Cells in Lupus
Christian M. Hedrich¹, José C. Crispín¹, Thomas Rauen¹, Christina Ioannidis¹, Tomohiro Koga², Noe Rodriguez Rodriguez², Sokratis A. Apostolidis³, Vasileios C. Kyttaris² and George C. Tsokos¹, ¹Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA, ²Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: CD3+CD4-CD8- "double negative" T cells are expanded in the peripheral blood of patients with systemic lupus erythematosus (SLE) and lupus-prone mice. Double negative T…
Abstract Number: 1637 • 2013 ACR/ARHP Annual Meeting
IKZF1 Modulates PP2Ac Expression Through An Intronic Binding Site
Kamalpreet Nagpal¹, Katsue S. Watanabe² and George C. Tsokos³, ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
IKZF1 modulates PP2Ac expression through an intronic binding siteKamalpreet Nagpal1, Katsue Sunahori2, George C. Tsokos11Department of Medicine, Division of Rheumatology, Beth Israel Deaconess Medical Center,…
Abstract Number: 1062 • 2013 ACR/ARHP Annual Meeting
The Brief Index Of Lupus Damage As a Predictor Of Mortality In a Cohort Of Patients With Systemic Lupus Erythematosus
Stephanie Rush¹, Laura Trupin², Jinoos Yazdany² and Patricia P. Katz², ¹University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA
The Brief Index of Lupus Damage as a Predictor of Mortality in a Cohort of Patients with Systemic Lupus Erythematosus Background/Purpose: To examine whether a…
Abstract Number: 607 • 2013 ACR/ARHP Annual Meeting
Venous Thromboembolic Disease Is Associated With Increased Length Of Stay and In-Hospital Mortality In Hospitalized SLE Patients: A Multi-State, Population-Based Study
Matthew Cascino¹, Laura Trupin¹, Sara Murray¹, Mary Margaretten², Edward H. Yelin³ and Jinoos Yazdany¹, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³Arthritis Research Group, University of California, San Francisco, San Francisco, CA
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) are at increased risk for venous thromboembolism (VTE). However, there is limited population-based data on outcomes associated with…
Abstract Number: 931 • 2012 ACR/ARHP Annual Meeting
Health Care Utilization Among Medicaid Enrollees with Systemic Lupus Erythematosus Preceding the Development of End-Stage Renal Disease: Sociodemographic Variation
Candace H. Feldman¹, Linda T. Hiraki², Graciela S. Alarcon³, Jinoos Yazdany⁴, Jun Liu⁵, Michael A. Fischer⁶, Wolfgang C. Winkelmayer⁷ and Karen H. Costenbader⁸, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital/ Harvard School of Public Health, Boston, MA, ³Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of California, San Francisco, San Francisco, CA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ⁶Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁷Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁸Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Extreme sociodemographic disparities exist among systemic lupus erythematosus (SLE) patients in the development of end-stage renal disease (ESRD) from lupus nephritis. Better resource allocation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].